Prognosis
CureVac Drops After Full Data Show Covid Shot Trails Rivals
This article is for subscribers only.
CureVac NV said its messenger RNA-based Covid-19 vaccine provided full protection against hospitalization and death for people under age 60, though its overall efficacy trailed that of similar shots already in use around the world.
The German company said in a statement late Wednesday that its vaccine was 48% effective at preventing disease of any severity. That is slightly higher than seen in a preliminary readout of the trial results but well behind the efficacy rates of more than 90% shown by Pfizer Inc. and Moderna Inc.’s mRNA shots.